The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.

The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

COMy 2022 | How the amyloidosis treatment landscape has transformed in recent years

Name: How the amyloidosis treatment landscape has transformed in recent years
Uploaded: 2022-05-12T00:00:00Z
Duration: 1 min 2 s

Joan Bladé • 12 May 2022

COMy 2022

Amyloidosis Multiple Myeloma Rare Diseases Antibodies Bortezomib Cyclophosphamide Daratumumab Dexamethasone Melphalan

Joan Bladé, MD, PhD, University of Barcelona, Barcelona, Spain, briefly discusses how the amyloidosis treatment landscape has transformed with the addition of daratumumab to cyclophosphamide, bortezomib, and dexamethasone, and the exciting implications that this combination therapy has for the future of amyloidosis treatment. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.